https://scientific-jl.com/luch/
Часть-40_ Том-2_ Март-2025
37
EVALUATION OF THE EFFECTIVENESS OF
CHONDROPROTECTORS IN THE TREATMENT OF
OSTEOARTHRITIS
Khamrayev Khamza Khamidullayevich
Husinov Akobir
Samarkand State Medical University Department of Internal Medicine
Abstract: Osteoarthritis (OA) is one of the most prevalent degenerative joint
diseases, characterized by progressive cartilage degradation, joint pain, and
functional limitation. Chondroprotectors, including glucosamine sulfate and
chondroitin sulfate, have been widely used as therapeutic agents aimed at
protecting cartilage, reducing inflammation, and improving joint function. This
article aims to evaluate the clinical efficacy of chondroprotective agents in the
management of osteoarthritis based on recent studies and clinical observations.
Findings suggest that chondroprotectors may provide moderate pain relief and
improve physical function in some patients, particularly during early stages of OA.
However, variations in study results emphasize the need for standardized
guidelines and further high-quality trials.
Keywords: osteoarthritis, chondroprotectors, glucosamine, chondroitin
sulfate, cartilage protection, joint pain
Introduction:
Osteoarthritis is a chronic degenerative disorder of synovial joints, primarily
affecting the elderly population. It involves deterioration of articular cartilage,
changes in subchondral bone, synovial inflammation, and formation of
osteophytes. Despite its high prevalence and substantial impact on quality of life,
https://scientific-jl.com/luch/
Часть-40_ Том-2_ Март-2025
38
therapeutic options remain limited to symptom management and surgical
intervention in advanced stages. In recent years, chondroprotectors have gained
attention for their potential to alter disease progression and provide symptomatic
relief. This article explores the role of chondroprotectors in OA treatment and
assesses their clinical efficacy based on current evidence.
Materials and Methods:
This study included a literature review of randomized controlled trials
(RCTs), cohort studies, and meta-analyses from databases such as PubMed,
Scopus, and ScienceDirect, published between 2010 and 2024. Inclusion criteria
were studies evaluating the efficacy of chondroprotectors in patients with knee or
hip osteoarthritis. Parameters assessed included pain relief (VAS score),
improvement in physical function (WOMAC index), and structural progression
(radiographic analysis). Both monotherapy and combination therapy of
glucosamine and chondroitin sulfate were evaluated.
Results:
Several
studies
demonstrated
that
chondroprotectors,
particularly
glucosamine sulfate and chondroitin sulfate, resulted in statistically significant
improvements in pain and physical function compared to placebo. Some trials
reported delayed radiographic progression of joint space narrowing. However, the
extent of benefit varied depending on the stage of OA, dosage, duration of
treatment, and patient characteristics. In combination therapy, synergistic effects
were more evident compared to monotherapy.
Discussion:
The findings suggest that chondroprotectors can play a supportive role in
managing osteoarthritis, particularly in early or moderate stages. While some
patients may experience notable symptom improvement, others may report
https://scientific-jl.com/luch/
Часть-40_ Том-2_ Март-2025
39
minimal benefit. Discrepancies among study outcomes could be attributed to
heterogeneity in study design, patient populations, and outcome measures.
Additionally, the placebo effect in OA treatment trials complicates interpretation
of efficacy. Long-term studies with standardized protocols are essential to establish
clear clinical guidelines for chondroprotective use.
Conclusion:
Chondroprotectors represent a promising adjunct in the conservative
management of osteoarthritis. Their ability to reduce symptoms and potentially
delay disease progression makes them valuable, especially in the early phase of
OA. Nevertheless, more comprehensive and standardized research is needed to
confirm their long-term effectiveness and optimize treatment protocols.
References:
1. Reginster JY, et al. (2013). Glucosamine and chondroitin sulfate in the
treatment of osteoarthritis. Arthritis & Rheumatism.
2. Hochberg MC, et al. (2016). Efficacy of chondroitin sulfate and
glucosamine for osteoarthritis: A meta-analysis. BMJ.
3. Wandel S, et al. (2010). Effects of glucosamine, chondroitin, or placebo in
osteoarthritis: Meta-analysis. BMJ.
4. Henrotin Y, et al. (2012). The role of glucosamine in the treatment of
osteoarthritis. Current Rheumatology Reports.
5. Vlad SC, et al. (2007). Glucosamine for osteoarthritis: A meta-analysis.
Annals of Internal Medicine.
https://scientific-jl.com/luch/
Часть-40_ Том-2_ Март-2025
40
6. McAlindon TE, et al. (2014). Clinical guidelines for the treatment of
osteoarthritis. American College of Rheumatology.
7. Bruyere O, et al. (2014). Effects of long-term glucosamine and
chondroitin use on OA progression. Osteoarthritis and Cartilage.
8. Jordan KM, et al. (2003). EULAR recommendations for osteoarthritis
management. Annals of Rheumatic Diseases.
9. Pavelka K, et al. (2010). Chondroprotective agents in OA: Clinical trial
outcomes. Rheumatology International.
10. Pelletier JP, et al. (2015). Disease-modifying properties of glucosamine
and chondroitin. Osteoarthritis and Cartilage.
